Document text
Principal Investigator: Duane R. Wesemann
Organization: BRIGHAM AND WOMEN'S HOSPITAL
Fiscal Year: 2021
Award: $3,169,124
Funding agency: National Institute of Allergy and Infectious Diseases
PROJECT 1 SUMMARY
Global establishment of Severe Acute Respiratory Syndrome (SARS) Coronavirus (CoV)-2 is a continued
human threat. While successful vaccine programs are well underway, genetic drift and immune escape have
already begun to subvert immunity. In addition, related zoonotic coronaviruses threaten transition into the
human population. CoVs can be highly transmissible and highly lethal, posing a grave threat to human lives
and world economies. In this light, developing pan-CoV vaccine options in preparation for the expected broad
range of SARS-CoV-2 variants and future emergent coronaviruses could save millions of lives and prevent
future global catastrophes. While current SARS-CoV-2 vaccines targeting the virus spike (S) protein hold great
promise in providing protection against current circulating strains, research is urgently needed to understand
breadth and durability of immunity across the CoV family and to translate this information into next generation
vaccines with increased breadth to cover SARS-CoV-2 escape mutants as well as to address emergent CoVs.
The overall goal of this program is to produce critical information necessary for the design and testing of next
generation CoV vaccine strategies with the greatest possible breadth across the CoV family. The Program
team will identify humoral, cellular, and structural immunologic features influencing clinical outcomes and
immune recognition breadth in human SARS-CoV-2 infection and human vaccination cohorts to fuel design
and pre-clinical testing of protective coronavirus vaccine strategies to identify those with the greatest possible
breadth. Project 1’s goal in this process is to define B cell/serologic properties of broad CoV immunity and
identify vaccine delivery conditions that can best support them. Preliminary discoveries from Project 1 together
with recent literature support the working hypothesis that aspects of vaccine strategy such as antigen choice,
delivery timing, dose, and valency will influence CoV recognition breadth and effectiveness. Knowledge gained
from strategic analysis of the heterogeneity of active human SARS-CoV-2 convalescent and vaccine cohorts
will generate new hypotheses to integrate into pre-clinical vaccine testing approach. In particular, recent work
from Project 1 investigators has identified the conserved S2 domain as promising target for broad CoV
immunity in humans. Program 1’s roles in evaluating these hypotheses are to: 1) identify immune correlates of
convalescent COVID-19 patients and vaccinees that exhibit superior durability and cross-reactivity; 2) define
the mechanisms of cross-reactive monoclonal mediated protection against CoVs in vivo; and 3) evaluate the
efficacy of novel vaccine immunogens to induce protective B cell/functional serological responses in animals.
Supported by Core B, results from Project 1 will provide strategic antibody, serological and memory B cell
analysis in the context of an integrative programmatic approach in synergy with Projects 2 and 3 approach to
generate vaccine strategies with maximal breadth and effectiveness.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><Address><Animals><Antibodies><Antibody Response><Antigens><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><COVID infected patient><COVID patient><COVID positive patient><COVID-19><COVID-19 infected patient><COVID-19 infection><COVID-19 patient><COVID-19 positive patient><COVID-19 vaccination><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID19><COVID19 infection><COVID19 patient><COVID19 positive patient><COVID19 vaccination><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cell Body><Cell Components><Cell Structure><Cells><Cellular Structures><Clinical><CoV emergence><CoV-2><CoV2><Containment><Coronaviridae><Coronavirus><Data><Dose><Effectiveness><Escape Mutant><Exhibits><Family><Future><Genetic Differentiation><Genetic Divergence><Genetic Drift><Goals><Hand><Heterogeneity><Human><Humoral Immunities><Immune><Immune memory><Immune response><Immunes><Immunity><Immunochemical Immunologic><Immunologic><Immunologic Memory><Immunological><Immunological Memory><Immunological response><Immunologically><Immunologics><Infection><Investigators><Knowledge><Light><Literature><Maps><Mediating><Memory B Cell><Memory B-Lymphocyte><Modeling><Modern Man><Outcome><Photoradiation><Population><Preclinical Testing><Preparation><Process><Property><Proteins><Research><Research Personnel><Researchers><Role><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 infected patient><SARS-CoV-2 infection><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-CoV-2 vaccination><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 infection><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Serology><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 vaccination><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Somatic Mutation><Source><Testing><Training><Translating><Vaccination><Vaccines><Virus><Work><Wuhan coronavirus><anamnestic reaction><antibody-based immunity><cohort><corona virus><corona virus disease 2019><corona virus disease 2019 vaccine><corona virus emergence><coronavirus disease 2019><coronavirus disease 2019 infected patient><coronavirus disease 2019 infection><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 vaccination><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease infected patient><coronavirus disease patient><coronavirus disease positive patient><coronavirus emergence><coronavirus patient><coronavirus vaccine><cross reactivity><deliver vaccines><design><designing><develop a vaccine><development of a vaccine><efficacy analysis><efficacy assessment><efficacy evaluation><efficacy examination><emergent CoV><emergent corona virus><emergent coronavirus><emerging CoV><emerging corona virus><emerging coronavirus><evaluate efficacy><evaluate vaccines><examine efficacy><hCoV19><host response><immune system response><immunogen><immunoresponse><in vivo><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><nCoV><nCoV2><new CoV><new corona virus><new coronavirus><new vaccines><next generation><next generation vaccines><novel CoV><novel corona virus><novel coronavirus><novel vaccines><pan CoV vaccine><pan coronavirus vaccine><pathogen><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><pre-clinical><pre-clinical testing><preclinical><prevent><preventing><programs><protective efficacy><response><secondary immune response><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><social role><synergism><tool><universal CoV vaccine><universal coronavirus vaccine><vaccinate against COVID-19><vaccinate against COVID19><vaccinate against SARS-CoV-2><vaccinate against coronavirus disease 2019><vaccinate against severe acute respiratory syndrome coronavirus 2><vaccination against COVID-19><vaccination against COVID19><vaccination against SARS-CoV-2><vaccination against Severe acute respiratory syndrome coronavirus 2><vaccination against coronavirus disease 2019><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine against coronavirus><vaccine delivery><vaccine development><vaccine evaluation><vaccine for novel coronavirus><vaccine formulation><vaccine screening><vaccine testing><zoonotic CoV><zoonotic coronavirus>